Pre-Conference Workshop Day
Pre-Conference Workshop Day
Tuesday 25th June 2024
8:00 am Check-In & Coffee
Workshop A
Exploring Strategic Insights into the Commercial Strategy Implications of the Inflation Reduction Act for Cell & Gene Therapy Administration to Ensure Strategic Advantages for Future Development Initiatives
Synopsis
Cell and gene therapies have some of the highest manufacturer prices in the US and so are an obvious target for negotiation. Therefore, the CMS is proceeding with implementing the provisions of the 2022 IRA. This legislation is expected to set upper limits on the negotiated price between manufacturers and US government-funded drug plans for high-budget impact drugs. So, how is this expected to affect the cell and gene therapy landscape?
Join to:
- Delve into the implications of the CMMI’s “Cell and Gene Therapy Access Model,” assessing whether drugs fall within the provisions of the Inflation Reduction Act (IRA), providing clarity on regulatory impacts
- Understand the commercial strategy implications of the Inflation Reduction Act (IRA) concerning the administration of cell and gene therapies in hospital and outpatient settings, enabling informed decision-making in different healthcare environments
- Explore strategic pathways by focusing on the development of cell and gene therapies within orphan indications with prevalent conditions, aiming to avoid or delay the impact of the Inflation Reduction Act (IRA) in the future
12:00 pm Networking Break
1:00 pm
Workshop B
A Comprehensive Approach to Understanding, Evaluating & Planning for the Commercialization of Transformative Cell & Gene Therapies to Gain Insights into the Challenges Faced, Forming a Robust Foundation for Strat
Synopsis
This session will help you understand, evaluate and plan for the commercialization of cell and gene therapies in the healthcare landscape. It encompasses financial considerations, patient outcome monitoring, commercial adoption, addressing challenges, ensuring patient coverage, and strategizing for future therapy delivery.
Join to:
- Gain insights into the evolving landscape of public payment dynamics following cell and gene therapy approvals across different states, exploring trends and variations
- Review the progress made and challenges encountered in the deployment of these therapies, equipping yourself with strategic insights on how to effectively prepare for large-scale delivery
- Develop a robust pricing strategy by building a value-based approach grounded in evidence, ensuring informed decisions and a successful launch of transformative therapies